The JNJ Patent Cliff Myth: A Distraction from Real Growth The Johnson & Johnson patent cliff has been touted as a major concern for investors, but is it truly the story that needs to be told?
Amidst the fixation on STELARA's impending expiration, a more significant narrative has quietly unfolded.
By examining the company's diversified portfolio and its growth drivers, we can see that the real story lies not in individual products, but in the compounding effects of multiple small advances.